Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sirolimus-eluting coronary stent - JW Medical Systems

Next Previous
Drug Profile

Sirolimus-eluting coronary stent - JW Medical Systems

Alternative Names: Excel; Excel DES; Excel-II

Latest Information Update: 30 Dec 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator JW Medical Systems
  • Class Anti-infectives; Anti-inflammatories; Antiepileptic drugs; Antifungals; Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Lactones; Macrolides; Nootropics; Polyenes; Pyridines; Skin disorder therapies
  • Mechanism of Action Immunosuppressants; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Coronary artery disease
  • Phase II/III Coronary artery restenosis

Most Recent Events

  • 26 Sep 2019 EXCEL-II sirolimus-eluting coronary stent is still in phase II/III trials for Coronary artery disease (Treatment-naive) and Coronary artery restenosis (Prevention) in China
  • 12 Feb 2015 JW Medical systems completes enrolment in its phase II trial for Coronary artery disease (treatment naive) in China (9174729; NCT02057978)
  • 12 Mar 2014 Phase-II clinical trials in Coronary artery disease (treatment-naive) in China (Intracoronary)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top